Search hospitals > Texas > Arlington
Arlington Research Center, Inc.
Claim this profileArlington, Texas 76011
Global Leader in Eczema
Global Leader in Atopic Dermatitis
Conducts research for Psoriasis
Conducts research for Plaque Psoriasis
Conducts research for Hidradenitis Suppurativa
62 reported clinical trials
1 medical researcher
Summary
Arlington Research Center, Inc. is a medical facility located in Arlington, Texas. This center is recognized for care of Eczema, Atopic Dermatitis, Psoriasis, Plaque Psoriasis, Hidradenitis Suppurativa and other specialties. Arlington Research Center, Inc. is involved with conducting 62 clinical trials across 30 conditions. There are 1 research doctors associated with this hospital, such as Angela Moore.Top PIs
Clinical Trials running at Arlington Research Center, Inc.
Atopic Dermatitis
Hidradenitis Suppurativa
Eczema
Sleep Disorders
Psoriasis
Plaque Psoriasis
Alopecia
Alopecia Areata
Ruxolitinib Cream
for Atopic Dermatitis/Eczema
This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.
Recruiting3 awards Phase 48 criteria
Upadacitinib
for Eczema
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab Dose A. Based on the participants response to upadacitinib Dose A, they may have their dose increased to upadacitinib Dose B after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult participants ages 18 to 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 94 sites worldwide. The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting2 awards Phase 32 criteria
Upadacitinib vs Dupilumab
for Eczema
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for treating AD patients aged 12 or older. Participants will receive upadacitinib (given as daily dose) or dupilumab (given at label indicated dose every 2 or 4 weeks). Participants will be stratified depending on disease severity, age and response to previous treatment. There is 1 in 5 chance for participants to receive dupilumab during the randomized cohort. Approximately 675 participants aged 2 to less than 12 years of age will be enrolled in this study at approximately 150 sites worldwide. The study population (As defined by participants age or prior treatment) to be enrolled in the study is dependent on local regulatory requirement and/or agreement. Participants will receive upadacitinib oral tablets once daily (or oral solution twice a day) for 160 weeks, or dupilumab as per its label for 52 weeks, and followed for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by clinical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Arlington Research Center, Inc.?
Arlington Research Center, Inc. is a medical facility located in Arlington, Texas. This center is recognized for care of Eczema, Atopic Dermatitis, Psoriasis, Plaque Psoriasis, Hidradenitis Suppurativa and other specialties. Arlington Research Center, Inc. is involved with conducting 62 clinical trials across 30 conditions. There are 1 research doctors associated with this hospital, such as Angela Moore.